Esperion Therapeutics Inc (ESPR)
2.05
+0.01
(+0.49%)
USD |
NASDAQ |
May 02, 10:32
Esperion Therapeutics Cash from Investing (Quarterly): 0.00 for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 17.50M |
| March 31, 2023 | 25.00M |
| December 31, 2022 | -11.79M |
| September 30, 2022 | 33.00M |
| June 30, 2022 | 5.00M |
| March 31, 2022 | -18.10M |
| December 31, 2021 | -50.48M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | -12.68M |
| September 30, 2020 | 2.333M |
| June 30, 2020 | 5.11M |
| March 31, 2020 | 26.59M |
| December 31, 2019 | -2.868M |
| September 30, 2019 | -5.313M |
| June 30, 2019 | 26.72M |
| March 31, 2019 | 45.70M |
| December 31, 2018 | 38.57M |
| September 30, 2018 | 40.03M |
| June 30, 2018 | 31.57M |
| March 31, 2018 | 30.28M |
| Date | Value |
|---|---|
| December 31, 2017 | 48.40M |
| September 30, 2017 | -127.52M |
| June 30, 2017 | 27.10M |
| March 31, 2017 | 16.17M |
| December 31, 2016 | 7.752M |
| September 30, 2016 | 13.07M |
| June 30, 2016 | 19.26M |
| March 31, 2016 | -29.96M |
| December 31, 2015 | 5.345M |
| September 30, 2015 | -37.26M |
| June 30, 2015 | -70.61M |
| March 31, 2015 | -57.55M |
| December 31, 2014 | -38.88M |
| September 30, 2014 | 0.785M |
| June 30, 2014 | 0.347M |
| March 31, 2014 | 1.153M |
| December 31, 2013 | -7.654M |
| September 30, 2013 | -13.39M |
| June 30, 2013 | 0.037M |
| March 31, 2013 | 0.001M |
| December 31, 2012 | 0.0016M |
| September 30, 2012 | 0.0026M |
| June 30, 2012 | 0.00 |
| March 31, 2012 | -0.0062M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-50.48M
Minimum
Dec 2021
33.00M
Maximum
Sep 2022
2.106M
Average
--
Median
Mar 2021
Cash from Investing (Quarterly) Benchmarks
| United Therapeutics Corp | 42.10M |
| Dynavax Technologies Corp | -20.24M |
| Heron Therapeutics Inc | -8.836M |
| Aldeyra Therapeutics Inc | 0.00 |
| Deciphera Pharmaceuticals Inc | 2.199M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.06M |
| Cash from Financing (Quarterly) | 4.471M |
| Free Cash Flow | -135.49M |
| Free Cash Flow Per Share (Quarterly) | -0.3294 |
| Free Cash Flow to Equity (Quarterly) | -37.49M |
| Free Cash Flow Yield | -64.16% |